Spectrometry News and Research

RSS

Waters first quarter sales rise 16% to $428 million

Waters Corporation reported first quarter 2011 sales of $428 million, an increase of 16%, from sales of $368 million in the first quarter of 2010. In the quarter, foreign currency translation added 2% to sales growth.

26 Apr 2011

Intrinsic Bioprobes launches mass spectrometry-based protein assays for in-vitro diagnostic testing

Intrinsic Bioprobes Inc. ("IBI") today announced the launch of its first mass spectrometry-based protein assays for in-vitro diagnostic testing. The assays for beta-2-microglobulin, cystatin C, and retinol binding protein are performed on IBI's MASSAY® platform at the CLIA-certified and College of American Pathology (CAP) accredited diagnostic laboratory of the Institute of Genomics Medicine, UMDNJ-New Jersey Medical School.

20 Apr 2011

SERI selects AB SCIEX TripleTOF 5600 system to test chronic eye inflammations

AB SCIEX, a global leader in life science analytical technologies, today announced that the Singapore Eye Research Institute, an internationally known eye research center, will advance biomarker candidates it identified for chronic inflammatory eye conditions into large-scale clinical trials for validation with the AB SCIEX TripleTOF™ 5600 System.

20 Apr 2011

Normal breast cells provide an innate defense mechanism against cancer

It is well known that the human body has a highly developed immune system to detect and destroy invading pathogens and tumor cells. Now, researchers at the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have shown that the body has a second line of defense against cancer - healthy cells.

15 Apr 2011

Researchers determine age of atherosclerotic plaques using carbon dating

In a new study performed in humans, researchers from Sweden's Karolinska Institutet have determined the age of atherosclerotic plaques by taking advantage of Carbon-14 residues in the atmosphere, prevailing after the extensive atomic bomb tests in the 50ties and 60ties.

8 Apr 2011

Bruker receives Health Canada approval for IVD MALDI Biotyper

At the 2011 Annual Meeting of the Canadian Association for Clinical Microbiology and Infectious Diseases, the companies i2A Canada and Bruker Ltd. announced together that they have met the relevant Health Products and Food Branch of Health Canada regulations for the Bruker IVD MALDI Biotyper, and that this product is now available for sale as a Class 1 Medical Device to all clinical microbiology sites in Canada.

8 Apr 2011

Molecular switch regulating protein behavior increases human susceptibility to schizophrenia, mood disorders

Johns Hopkins researchers report the discovery of a molecular switch that regulates the behavior of a protein that, when altered, is already known to increase human susceptibility to schizophrenia and mood disorders.

7 Apr 2011

Nanotechnology can help better assess whether cancer drugs hit their targets

A Purdue University biochemist has demonstrated a process using nanotechnology to better assess whether cancer drugs hit their targets, which may help reduce drug side effects.

6 Apr 2011

Bruker closes acquisition of Michrom

Bruker today announced the closing of its acquisition of Michrom Bioresources, Inc. (Michrom), a 20 year old, privately owned company located in Auburn, California, after receiving unanimous Michrom shareholder approval. The acquisition is not expected to have a material effect on Bruker's 2011 financials.

4 Apr 2011

Researchers study role of acetylation in Alzheimer's disease

Researchers at the University of Pennsylvania School of Medicine have determined that a well-known chemical process called acetylation has a previously unrecognized association with one of the biological processes associated with Alzheimer's disease and related disorders. The findings were published in the latest issue of Nature Communications.

1 Apr 2011

Researchers characterize novel form of ubiquitin regulatory protein

Researchers at the Proteome Center Tuebingen characterize a novel form of the regulatory protein ubiquitin, involved in inflammation and cell death.

31 Mar 2011

Labcyte launches 1536-well tissue-culture treated microplate for cell-based screening

Labcyte Inc. today launched a new 1536-well tissue-culture treated microplate for cell-based screening and discovery applications. By enabling cell culture directly in a high-density microplate, this new product expands cell-based assay miniaturization capabilities, such as direct PCR from cell cultures.

30 Mar 2011

NeoProteomics secures exclusive option agreement with Case Western Reserve University

NeoProteomics Inc., a biomarker development and software company, has secured an exclusive option agreement with Case Western Reserve University. The deal has potential to enhance various forms of treatment of cancer, diabetes, and inflammatory diseases.

28 Mar 2011

Biognosys brings proteomic breakthroughs to mainstream users

Biognosys, a leading provider of targeted proteomics solutions, announces the software platform mProphet for large-scale applications in industrial and academic research. The software was recently published in «Nature Methods»: With the new tool researchers can analyze complex proteomics data and generate statistically validated results.

From Biognosys 25 Mar 2011

Study develops new approaches for sorting out complexities of cancer cells

New drugs that specifically target the mutated genes responsible for cancer growth have shown great success in extending the lives of patients, with far fewer side effects than conventional anti-cancer therapies. Unfortunately, many patients become resistant to these drugs due to secondary mutations.

25 Mar 2011

Agilent opens new lab facility in Bangalore, India

Agilent Technologies Inc. has expanded its Life Sciences and Chemical Analysis Center of Excellence in Bangalore.

25 Mar 2011

NextGen Sciences introduces multiplex protein assay for oncology biomarker discovery

NextGen Group plc is pleased to announce that its subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first multiple protein assay, plasmadiscovery41, for oncology biomarker discovery and qualification.

16 Mar 2011

NextGen Group subsidiary completes commercial reorganization

NextGen Group plc is pleased to announce that its subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has completed a commercial reorganization. The restructuring, which is accompanied by new management appointments, is expected to help the company execute its strategy of becoming a leading player in the growing oncology and central nervous system (CNS) biomarker markets.

10 Mar 2011

First urinary metabolomic investigation in gastric cancer using gas chromatography/mass spectrometry

Metabolomics is a post-genomic research field for analysis of low molecular weight compounds in biological systems, and its approaches offer an analysis of metabolite level changes in biological samples. Recently, metabolomic method has shown great potentials in identifying the new diagnostic markers and therapeutic targets for cancers. However, metabolomic studies on cancer metastasis remain scarce.

9 Mar 2011

'Cross-talk' between two major biological pathways may hold a clue for chronic pain treatment

Researchers at the University of California, Davis have discovered a "cross-talk" between two major biological pathways that involve pain-research that may pave the way to new approaches to understanding and controlling chronic pain.

9 Mar 2011